Recently literature revealed facts, that show H+/K+ ATPase expression is not limited tot he stomach. H+/K+ ATPase was also found in smooth muscle cells and in other tissues (McCabe, R.D. et al., Am J Physiol. 1992). For myocard a localisation is only proven for rats yet (Beisvag, V. et al., Acta Physiol Scand. 2003). Moreover biochemical hints lead us to a highly probability of a myocardial H+/K+ ATPase (Nagashima, R. et al., Jpn Heart J. 1999).
Conditions
Interventions
Product Name: Pantoprazol
Pharmaceutical Form: Powder for solution for injection
INN or Proposed INN: Pantoprazol
Concentration unit: mg milligram(s)
Sponsors
Johann Wolfgang Goethe Universität
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Only patients older than 18 years. Range 18 to 80 years. 2. Only cooperative patients. 3. Only patients with a need for a coronary angiography, independently from our study. 4. Only patients with a left ventricular ejection fraction as demanded in the study protocol. 5. Only patients with clinical symptoms of congestive heart failure, corresponding to New York Heart Association stage NYHA II or III. 6. Only patients without oral or i.v. application of a proton pump inhibitor up to 48 hours prior to the study catherization. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Manifest or severe accompanying diseases, despite of diabetes mellitus. 2. Intravascular or oral application of proton pump inhibitors within the last 48 hours. 3. Intake of Metformin within the last 24 hours. 4. Status post heart transplant. 5. Pregnancy. 6. Known intolerance of pantoprazole 7. severe side effects of the tested substance pantoprazole, as well as pharmacokinetic interactions through CYP isoenzymes 8. Existance of side effects as given in the pantoprazole drug information, among others disturbances of blood- and lymphatic system, leukopenia, thrombopenia, affections of gastrointestinal tract, nerve system affections, psychiatric affections, renal or bladder affections. 9. Participation in a other clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Aim of our clinical study is to examine, whether proton pump inhibitors have an influence on myocardial contraction of human myocard and we want to ascertain the amount of influence of a H+/K+ ATPase on myocardial contraction. Therefore the mechanism of a putative inhibition by proton pump inhibitors is at our focus. These findings will be of major credit regarding treatment of patients with congestive heart failure with common proton pump inhibitors. We want to find out, whether this intake may have a negative inotropic effect on the heart failure myocard.;Secondary Objective: ;Primary end point(s): Primary end point is negative influence of proton pump inhibitors on hemodynamics in sense of negative inotropic effects on human myocard. | — |
Countries
Germany
Outcome results
None listed